Lack of Mutations in Protein Tyrosine Kinase Domain Coding Exons 19 and 21 of the EGFR Gene in Oral Squamous Cell Carcinomas

Mehta, Dhaval Tushar; Thangavelu, Arthiie; Ramanathan, Arvind

doi:10.7314/apjcp.2014.15.11.4623

Cited by 5 publications

(4 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Together, these studies suggest that EGFR GCN may have some clinical utility in the risk management of OPMD, but is not sufficiently predictive to be used as a standalone biomarker. Although the frequency of EGFR mutations documented in OSCC is low (40)(41)(42), it is a limitation of the current study that neither EGFR mutation status nor downstream EGFR targets were evaluated. It is possible that EGFR GCN represents a "surrogate" marker for other genetic and molecular abnormalities and simply reflects chromosomal instability; nevertheless, the positive correlation between EGFR GCN and protein overexpression suggests that increased EGFR GCN may be functionally relevant.…”

Section: Cancer Epidemiol Biomarkers Prev; 25(6) June 2016mentioning

confidence: 97%

Changes in Epidermal Growth Factor Receptor Gene Copy Number during Oral Carcinogenesis

Bates

Kennedy

Diajil

et al. 2016

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

Background: Oral squamous cell carcinoma (OSCC) is a global healthcare problem associated with poor clinical outcomes. Early detection is key to improving patient survival. OSCC may be preceded by clinically recognizable lesions, termed oral potentially malignant disorders (OPMD). As histologic assessment of OPMD does not accurately predict their clinical behavior, biomarkers are required to detect cases at risk of malignant transformation. Epidermal growth factor receptor gene copy number (EGFR GCN) is a validated biomarker in lung non-small cell carcinoma. We examined EGFR GCN in OPMD and OSCC to determine its potential as a biomarker in oral carcinogenesis.Methods: EGFR GCN was examined by in situ hybridization (ISH) in biopsies from 78 patients with OPMD and 92 patients with early-stage (stages I and II) OSCC. EGFR ISH signals were scored by two pathologists and a category assigned by consensus.

show abstract

Section: Cancer Epidemiol Biomarkers Prev; 25(6) June 2016mentioning

confidence: 97%

Changes in Epidermal Growth Factor Receptor Gene Copy Number during Oral Carcinogenesis

Bates

Kennedy

Diajil

et al. 2016

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

show abstract

“…Surprisingly, Bernardes et al 30 demonstrated that EGFR expression was not dependent on the gene copy number in OSCC. Metha et al 28 and Tushar and Ramanathan 31 did not identify mutations in the EGFR gene in OSCC. This issue should be clarified in future genetic studies of EGFR in OL.…”

Section: Discussionmentioning

confidence: 96%

“…25 Accordingly, genetic alterations have been identified in EGFR genes in human cancers. [26][27][28] Thus, if OL cells have abnormal EGFR expression or function, they could overrespond to normal EGF levels. In accordance with this hypothesis, Ribeiro et al 29 demonstrated that EGFR immunoreactivity is common in OL, especially in high-risk lesions.…”

Section: Discussionmentioning

confidence: 99%

Is salivary epidermal growth factor a biomarker for oral leukoplakia? A preliminary study

Jaeger

Assunção

Caldeira

et al. 2015

Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology

View full text Add to dashboard Cite

show abstract

“…DNA extraction and Methylation Sensitive Restriction Digestion: Tissue genomic DNA was extracted as described earlier (Mehta, 2014). The digestion of total genomic DNA from all tumor samples were performed with 10U of methylation sensitive type II restriction endonuclease, HpaII (New England Biolabs, Ipswich, MA, USA) at 37°C for 4h in a 20µl reaction volume followed by inactivation by incubation of the reaction mix at 65°C for 20m.…”

Section: Methodsmentioning

confidence: 99%

BRD7 Promoter Hypermethylation as an Indicator of Well Differentiated Oral Squamous Cell Carcinomas

Balasubramanian¹,

Ramkumar²,

Narayanan³

et al. 2015

Asian Pacific Journal of Cancer Prevention

Self Cite

View full text Add to dashboard Cite

Background: Promoter hypermethylation mediated gene silencing of tumor suppressor genes is considered as most frequent mechanism than genetic aberrations such as mutations in the development of cancers. BRD7 is a single bromodomain containing protein that functions as a subunit of SWI/SNF chromatin-remodeling complex to regulate transcription. It also interacts with the well know tumor suppressor protein p53 to transactivate genes involved in cell cycle arrest. Loss of expression of BRD7 has been observed in breast cancers and nasopharyngeal carcinomas due to promoter hypermethylation. However, the genetic status of BRD7 in oral squamous cell carcinomas (OSCCs) is not known, although OSCC is one of the most common among all reported cancers in the Indian population. Hence, in the present study we investigated OSCC samples to determine the occurrence of hypermethylation in the promoter region of BRD7 and understand its prevalence. Materials and Methods: Genomic DNA extracted from biopsy tissues of twenty three oral squamous cell carcinomas were digested with methylation sensitive HpaII type2 restriction enzyme that recognizes and cuts unmethylated CCGG motifs. The digested DNA samples were amplified with primers flanking the CCGG motifs in promoter region of BRD7 gene. The PCR amplified products were analyzed by agarose gel electrophoresis along with undigested amplification control. Results: Methylation sensitive enzyme technique identified methylation of BRD7 promoter region seventeen out of twenty three (74%) well differentiated oral squamous cell carcinoma samples. Conclusions: The identification of BRD7 promoter hypermethylation in 74% of well differentiated oral squamous cell carcinomas indicates that the methylation dependent silencing of BRD7 gene is a frequent event in carcinogenesis. To the best of our knowledge, the present study is the first to report the occurrence of BRD7and its high prevalence in oral squamous cell carcinomas.

show abstract

Lack of Mutations in Protein Tyrosine Kinase Domain Coding Exons 19 and 21 of the EGFR Gene in Oral Squamous Cell Carcinomas

Cited by 5 publications

References 43 publications

Changes in Epidermal Growth Factor Receptor Gene Copy Number during Oral Carcinogenesis

Changes in Epidermal Growth Factor Receptor Gene Copy Number during Oral Carcinogenesis

Is salivary epidermal growth factor a biomarker for oral leukoplakia? A preliminary study

BRD7 Promoter Hypermethylation as an Indicator of Well Differentiated Oral Squamous Cell Carcinomas

Contact Info

Product

Resources

About